Lineage cell therapeutics, inc. (BTX)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
ASSETS
CURRENT ASSETS
Cash and cash equivalents

9,832

9,497

14,366

8,210

18,011

23,587

19,467

27,207

29,827

36,838

16,662

14,550

23,816

22,088

30,451

27,702

27,132

42,229

29,378

31,465

25,829

29,487

7,416

15,721

6,637

5,495

6,717

14,306

9,896

4,349

7,830

12,659

16,487

22,211

26,230

27,381

33,324

Marketable equity securities

15,933

21,219

21,318

8,477

9,085

7,154

1,972

1,948

-

1,337

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory note from Juvenescence (Note 5)

23,994

23,616

23,238

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Marketable equity securities

-

-

-

-

-

-

-

-

1,552

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash equivalents in escrow

-

-

-

-

-

-

-

-

-

-

-

5,100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Available-for-sale securities

-

-

-

-

-

-

-

-

-

-

1,511

1,220

915

627

903

619

829

753

-

-

-

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants and other accounts receivable

-

-

-

-

-

-

-

-

-

-

1,420

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Trade accounts and other receivables

-

-

-

-

-

-

-

-

-

-

-

360

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Trade accounts and grants receivable, net

253

317

157

1,671

1,402

767

721

1,693

916

780

-

-

206

446

1,604

783

1,125

1,078

944

979

866

1,042

1,014

1,190

818

1,115

-

-

-

-

-

-

-

-

-

-

-

Landlord receivable

-

-

-

-

-

840

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

260

297

299

266

253

257

236

178

61

64

52

55

56

55

54

51

61

56

45

Landlord receivable

-

-

-

-

-

-

-

-

-

-

-

-

0

200

115

156

943

567

1,525

2,771

277

378

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Receivables from affiliates, net

47

7

164

-

-

2,112

2,185

2,076

2,082

2,266

2,278

2,706

2,807

511

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loan receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

506

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

2,225

2,863

2,342

2,101

2,158

1,898

1,761

1,571

1,749

1,402

1,354

1,589

1,513

1,777

2,079

1,787

2,878

2,610

1,752

1,492

1,271

1,229

1,255

1,476

1,554

1,160

1,900

3,760

3,018

2,774

1,861

1,891

2,101

2,692

2,263

1,981

2,202

Total current assets

52,284

57,519

61,585

20,459

30,656

36,358

36,906

34,495

36,126

42,623

23,225

25,525

29,257

25,649

35,152

31,047

32,907

47,237

34,365

37,004

28,544

32,405

9,939

18,646

9,246

7,949

8,679

18,131

12,967

7,179

9,748

14,606

18,644

24,955

28,555

29,419

35,572

NONCURRENT ASSETS
Property and equipment, net (Notes 6 & 15)

7,539

8,175

8,844

8,720

8,918

5,835

5,117

5,014

5,366

5,533

5,423

5,240

4,992

5,529

4,726

4,062

8,932

7,539

6,781

5,652

2,864

2,858

2,758

2,982

2,959

2,997

2,905

1,841

1,741

1,348

1,251

1,298

1,385

1,347

1,291

1,217

710

Deferred license fees

-

-

-

-

-

-

-

-

-

-

-

-

90

-

145

173

293

322

-

-

-

337

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred license and consulting fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

712

756

-

-

-

-

-

Deposits and other long-term assets

637

864

826

815

890

505

518

229

236

1,018

1,005

1,014

977

1,149

1,011

1,022

1,268

1,299

-

446

443

453

435

435

428

129

126

118

118

64

67

67

63

63

65

65

51

Promissory note from Juvenescence (Note 5)

-

-

-

-

-

22,104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory note from Juvenescence (Note 5)

-

-

-

22,860

22,482

-

21,730

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity method investment

-

-

-

-

-

-

-

-

-

-

-

-

87,312

-

3,482

4,338

4,436

4,671

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Goodwill

10,672

10,672

12,977

12,977

12,977

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity method investment in Asterias, at fair value (Note 5)

-

-

-

-

-

-

-

-

-

-

-

-

73,942

-

92,210

52,194

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible assets, net

-

-

48,746

49,321

49,829

3,125

3,600

5,735

6,317

6,900

7,482

8,064

8,646

10,206

10,848

11,491

-

33,592

-

-

-

-

-

-

-

-

-

-

-

-

21,089

21,652

-

-

-

-

-

Deferred license fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

352

282

309

-

364

391

418

444

583

600

625

669

-

-

800

843

887

1,109

1,550

Deposits and other long-term assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

455

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

7

-

53

57

56

0

-

-

-

-

-

-

-

-

-

-

-

Intangible assets, net

47,750

48,248

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,278

-

34,906

36,220

37,534

38,848

42,104

43,472

44,840

46,208

18,559

19,201

19,844

20,486

-

-

18,083

18,619

20,076

21,645

15,386

TOTAL ASSETS

118,882

125,478

132,978

151,691

183,715

101,660

176,077

112,251

110,395

173,241

221,867

193,353

205,216

142,572

147,574

104,327

80,114

94,660

76,859

79,610

69,703

74,901

55,654

65,985

57,949

57,729

30,853

39,893

35,297

29,748

32,870

38,381

38,977

45,829

50,875

53,457

53,272

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable and accrued liabilities

5,321

5,226

4,842

6,859

7,336

6,463

4,082

5,028

4,703

5,718

5,360

5,130

6,947

7,144

7,176

6,508

10,674

9,377

7,793

6,604

6,322

6,803

5,550

4,741

5,443

6,722

4,201

3,972

3,901

3,989

2,162

2,485

1,502

2,681

2,251

2,779

1,929

Financing lease and right of use lease liabilities, current portion (Note 15)

1,240

1,223

1,138

956

954

237

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Escrow liability

-

-

-

-

-

-

-

-

-

-

-

5,100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capital lease and lease liability, current portion

-

-

-

-

-

-

231

225

222

212

0

0

0

202

173

173

22

38

46

58

57

58

57

57

-

0

-

-

-

-

-

-

-

-

-

-

-

Promissory notes, current portion

-

-

-

-

18

70

70

120

120

152

126

124

124

99

95

95

95

95

95

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred license and subscription revenues

-

-

-

-

-

-

-

-

-

488

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred grant revenue

-

-

-

44

43

-

-

-

-

309

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liability classified warrants, current portion

-

-

-

-

372

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Related party convertible debt

-

-

-

-

-

-

-

-

-

-

13

2,555

1,070

833

357

-

-

0

255

238

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred license and subscription revenues

-

-

-

-

-

-

77

367

563

-

-

-

-

572

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Related party convertible debt, net of discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

169

-

3

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Deferred grant income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,269

2,513

1,869

1,932

1,474

0

-

-

-

-

47

-

-

-

55

0

261

261

271

-286

261

Deferred revenues

200

-

182

-

-

42

43

103

202

-

513

621

679

0

537

627

609

439

278

360

178

208

177

270

177

235

349

462

394

400

354

476

201

203

199

220

288

Deferred grant revenue

208

45

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

6,969

6,494

6,162

7,859

8,723

6,812

4,503

5,843

5,810

6,879

6,012

13,530

8,820

8,850

8,338

7,403

13,669

12,462

10,336

9,192

8,202

7,069

5,788

5,069

5,620

6,957

4,598

4,434

4,295

4,390

2,572

2,962

1,965

3,146

2,722

3,286

2,479

LONG-TERM LIABILITIES
Deferred tax liability

3,315

3,315

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent liabilities, net of current portion

-

-

-

-

-

244

238

189

114

105

91

79

66

50

46

28

261

158

95

36

34

97

-

20

28

35

42

47

52

57

60

61

62

66

27

27

0

Deferred tax liability

-

-

6,343

7,334

8,581

-

-

-

-

-

4,845

-

3,877

-

-

-

-

-

1,119

2,067

3,337

4,515

10,787

14,244

6,928

8,277

-

-

-

0

-

-

-

-

-

-

-

Commitments and contingencies

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred revenues

-

200

240

200

200

-

-

-

-

-

77

154

231

308

385

462

538

615

-

-

-

0

-

-

-

-

644

693

732

768

790

826

863

899

936

975

1,048

Right-of-use lease liability, net of current portion (Note 15)

3,527

3,868

4,087

3,825

4,016

1,854

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing lease, net of current portion

66

77

87

93

103

104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability, net of current portion

-

-

-

-

-

-

1,221

915

968

1,019

1,257

1,301

1,344

1,386

1,348

1,386

5,408

4,400

4,089

3,331

560

378

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Capital lease, net of current portion

-

-

-

-

-

-

110

116

122

132

0

0

0

310

89

122

32

26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Capital lease liability, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3

17

31

44

57

-

0

-

-

-

-

-

-

-

-

-

-

-

Related party convertible debt, net of discount

-

-

-

-

-

-

-

-

-

-

0

0

1,077

1,032

954

701

394

324

-

-

-

60

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory notes, net of current portion

-

-

-

-

-

-

0

0

0

18

44

95

95

120

173

173

220

220

268

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liability classified warrants, net of current portion, and other long-term liabilities

247

277

540

621

856

400

447

437

926

825

-

-

-

8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

554

9

9

-

-

-

-

8

18

30

38

28

79

9

8

195

200

201

235

237

235

236

255

258

272

297

318

TOTAL LIABILITIES

14,124

14,231

17,459

19,932

22,479

9,414

6,519

7,500

7,940

8,978

12,880

15,168

15,519

12,064

11,333

10,275

-

18,213

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

TOTAL LIABILITIES

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20,522

-

5,589

5,467

3,989

5,109

10,911

14,331

6,965

8,509

886

941

1,019

1,063

1,085

1,124

1,181

1,224

1,236

1,301

1,367

Commitments and contingencies (Note 15)

-

-

-

-

-

-

-

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

SHAREHOLDERS' EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

3,500

3,500

3,500

3,500

3,500

3,500

0

0

0

0

0

0

0

-

0

0

0

0

Common shares, no par value, 250,000 shares authorized; 149,818 shares issued and outstanding as of March 31, 2020 and 149,804 shares issued and outstanding as of December 31, 2019

387,686

387,062

386,454

385,615

384,553

354,270

386,858

383,529

379,186

378,487

342,508

334,538

333,997

317,878

313,506

310,881

275,238

273,979

248,069

235,555

234,751

234,850

201,298

199,944

211,943

203,456

149,008

148,002

135,594

119,821

120,905

120,163

115,547

115,144

114,739

108,347

101,135

Contributed capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

-

59

59

93

93

93

93

93

93

93

93

93

93

93

93

93

Accumulated other comprehensive income (loss)

634

-681

-357

207

694

1,426

1,174

1,082

198

451

141

271

408

-738

-690

-504

-60

-237

-87

-131

238

186

-150

-85

-44

62

124

117

88

-59

-197

-181

1

-122

-99

-701

897

Accumulated deficit

-281,821

-273,422

-268,940

-252,435

-222,403

-261,856

-216,905

-283,630

-279,416

-216,297

-144,363

-158,684

-147,033

-196,321

-190,534

-221,743

-246,293

-229,893

-215,757

-202,055

-192,357

-182,190

-171,606

-163,387

-153,877

-145,778

-126,166

-117,178

-109,614

-101,895

-95,860

-90,899

-85,433

-80,470

-75,109

-71,596

-63,954

Treasury stock at cost: no shares as of December 31, 2017; 620 shares as of December 31, 2016

-

-

-

-

-

-

-

-

-

-

0

0

0

2,891

2,891

2,891

18,033

18,033

19,182

19,890

19,889

19,890

22,119

22,119

42,372

43,033

10,120

10,120

10,317

8,375

8,001

6,000

6,000

6,000

-6,000

-

0

Lineage Cell Therapeutics, Inc. shareholders' equity

106,499

112,959

117,157

133,387

162,844

93,840

171,127

100,981

99,968

162,641

198,286

176,125

187,372

117,928

119,391

85,743

10,852

25,816

13,043

16,979

26,250

36,456

10,981

17,912

19,242

14,800

12,940

20,915

15,844

9,584

16,939

23,176

24,199

28,646

33,624

36,143

38,172

Noncontrolling interest (deficit)

-1,741

-1,712

-1,638

-1,628

-1,608

-1,594

-1,569

3,770

2,487

1,622

10,701

2,060

2,325

12,580

16,850

8,309

48,740

50,631

47,891

47,972

31,261

26,267

27,973

28,672

26,121

27,461

12,428

13,601

14,137

14,709

12,271

11,117

11,631

12,812

13,291

12,725

11,253

Total shareholders' equity

104,758

111,247

115,519

131,759

161,236

92,246

169,558

104,751

102,455

164,263

208,987

178,185

189,697

130,508

136,241

94,052

59,592

76,447

60,934

64,951

57,511

62,723

38,954

46,584

45,364

42,262

25,368

34,517

29,982

24,294

29,211

34,294

35,831

41,458

46,916

48,869

49,425

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

118,882

125,478

132,978

151,691

183,715

101,660

176,077

112,251

110,395

173,241

221,867

193,353

205,216

142,572

147,574

104,327

80,114

94,660

76,859

79,610

69,703

74,901

55,654

65,985

57,949

57,729

30,853

39,893

35,297

29,748

32,870

38,381

38,977

45,829

50,875

53,457

53,272

OncoCyte Corporation [Member]
Equity method investment

-

-

-

36,539

57,963

20,250

-

-

-

68,235

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common shares, no par value, 250,000 shares authorized; 149,388 shares issued and outstanding as of March 31, 2019 and 127,136 shares issued and outstanding as of December 31, 2018

-

-

-

-

58,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Asterias Biotherapeutics [Member]
Equity method investment

-

-

-

-

-

13,483

-

-

-

48,932

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-